13 de mayo de 2016 / 10:47 / hace un año

BRIEF-Pfizer presents results from two Phase 3 trumenba studies

1 MIN. DE LECTURA

May 13 (Reuters) - Pfizer Inc

* Pfizer presents results from two Phase 3 trumenba(meningococcal Group B vaccine) studies at the European society for paediatric infectious diseases meeting

* Secondary data support that trumenba protects against additional meningococcal serogroup b strains

* Phase 3 data support additional global regulatory submissions for trumenba

* Phase 3 data also supports planned U.S. supplement to request conversion of accelerated approval to traditional approval for trumenba

* The two studies, one in adolescents and one in young adults, met all primary immunogenicity endpoints Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below